CN1671354A - 异黄酮在促进减肥中的应用 - Google Patents
异黄酮在促进减肥中的应用 Download PDFInfo
- Publication number
- CN1671354A CN1671354A CNA038180170A CN03818017A CN1671354A CN 1671354 A CN1671354 A CN 1671354A CN A038180170 A CNA038180170 A CN A038180170A CN 03818017 A CN03818017 A CN 03818017A CN 1671354 A CN1671354 A CN 1671354A
- Authority
- CN
- China
- Prior art keywords
- isoflavone
- application
- activating agent
- fat
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 235000008696 isoflavones Nutrition 0.000 title claims abstract description 43
- 150000002515 isoflavone derivatives Chemical class 0.000 title claims abstract description 7
- 230000001737 promoting effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims abstract description 63
- 239000000284 extract Substances 0.000 claims abstract description 34
- 230000000699 topical effect Effects 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 12
- 239000002537 cosmetic Substances 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 37
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 36
- 230000003213 activating effect Effects 0.000 claims description 30
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 19
- -1 rhodysterol Chemical compound 0.000 claims description 18
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 16
- 239000003925 fat Substances 0.000 claims description 15
- 230000003796 beauty Effects 0.000 claims description 14
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims description 14
- 241000628997 Flos Species 0.000 claims description 13
- 210000000582 semen Anatomy 0.000 claims description 12
- 230000013595 glycosylation Effects 0.000 claims description 11
- 238000006206 glycosylation reaction Methods 0.000 claims description 11
- 235000011201 Ginkgo Nutrition 0.000 claims description 8
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 8
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 8
- 229960001948 caffeine Drugs 0.000 claims description 8
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 8
- 208000020442 loss of weight Diseases 0.000 claims description 8
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 claims description 7
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 claims description 7
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 claims description 7
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 claims description 6
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 claims description 6
- 230000008485 antagonism Effects 0.000 claims description 6
- 229940011399 escin Drugs 0.000 claims description 6
- 229930186222 escin Natural products 0.000 claims description 6
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 claims description 6
- 210000003462 vein Anatomy 0.000 claims description 6
- 235000007240 daidzein Nutrition 0.000 claims description 5
- 235000008466 glycitein Nutrition 0.000 claims description 5
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 claims description 5
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 claims description 5
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 4
- 241000227647 Fucus vesiculosus Species 0.000 claims description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 4
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims description 4
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 4
- 235000005493 rutin Nutrition 0.000 claims description 4
- 229960004555 rutoside Drugs 0.000 claims description 4
- XOMRRQXKHMYMOC-NRFANRHFSA-N (3s)-3-hexadecanoyloxy-4-(trimethylazaniumyl)butanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H](CC([O-])=O)C[N+](C)(C)C XOMRRQXKHMYMOC-NRFANRHFSA-N 0.000 claims description 3
- 240000001307 Myosotis scorpioides Species 0.000 claims description 3
- 235000003500 Ruscus aculeatus Nutrition 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 238000001764 infiltration Methods 0.000 claims description 3
- 229940098465 tincture Drugs 0.000 claims description 3
- 244000194101 Ginkgo biloba Species 0.000 claims 2
- 244000046052 Phaseolus vulgaris Species 0.000 claims 2
- 241000086254 Arnica montana Species 0.000 claims 1
- 235000004032 Centella asiatica Nutrition 0.000 claims 1
- 244000146462 Centella asiatica Species 0.000 claims 1
- 244000046101 Sophora japonica Species 0.000 abstract 1
- 235000010586 Sophora japonica Nutrition 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 14
- 108010073771 Soybean Proteins Proteins 0.000 description 13
- 235000019197 fats Nutrition 0.000 description 13
- 235000019710 soybean protein Nutrition 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 235000006539 genistein Nutrition 0.000 description 11
- 229940045109 genistein Drugs 0.000 description 11
- 239000003531 protein hydrolysate Substances 0.000 description 11
- 210000001789 adipocyte Anatomy 0.000 description 10
- 229940005582 gotu kola extract Drugs 0.000 description 10
- 235000013599 spices Nutrition 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 230000002335 preservative effect Effects 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 7
- 239000007766 cera flava Substances 0.000 description 7
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 7
- 238000012423 maintenance Methods 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000218628 Ginkgo Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 5
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 5
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 5
- 229940086555 cyclomethicone Drugs 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 229940075529 glyceryl stearate Drugs 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 4
- KGKQNDQDVZQTAG-UHFFFAOYSA-N 8-methylnonyl 2,2-dimethylpropanoate Chemical compound CC(C)CCCCCCCOC(=O)C(C)(C)C KGKQNDQDVZQTAG-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 4
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 4
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 244000299461 Theobroma cacao Species 0.000 description 4
- 235000009470 Theobroma cacao Nutrition 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229930182478 glucoside Natural products 0.000 description 4
- 125000005456 glyceride group Chemical group 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 229940031674 laureth-7 Drugs 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 239000012752 auxiliary agent Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 239000007957 coemulsifier Substances 0.000 description 3
- 229920006037 cross link polymer Polymers 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 229920002545 silicone oil Polymers 0.000 description 3
- 239000004575 stone Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 241000208983 Arnica Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 240000003444 Paullinia cupana Species 0.000 description 2
- 235000000556 Paullinia cupana Nutrition 0.000 description 2
- DUFKCOQISQKSAV-UHFFFAOYSA-N Polypropylene glycol (m w 1,200-3,000) Chemical compound CC(O)COC(C)CO DUFKCOQISQKSAV-UHFFFAOYSA-N 0.000 description 2
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 229960000735 docosanol Drugs 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosanyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 239000008309 hydrophilic cream Substances 0.000 description 2
- 229940100556 laureth-23 Drugs 0.000 description 2
- 230000004132 lipogenesis Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940078812 myristyl myristate Drugs 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 229940059574 pentaerithrityl Drugs 0.000 description 2
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- TXLQONQJSWSJJX-UHFFFAOYSA-N 3,7-dimethyl-3(E),6-octadien-5-one-1-O-beta-D-glucoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC2=C1C(=O)C(C=1C=CC(O)=CC=1)=CO2 TXLQONQJSWSJJX-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UHFFFAOYSA-N 3-phosphoglyceric acid Chemical compound OC(=O)C(O)COP(O)(O)=O OSJPPGNTCRNQQC-UHFFFAOYSA-N 0.000 description 1
- FRAUJUKWSKMNJY-UHFFFAOYSA-N 5-hydroxy-3-(4-hydroxyphenyl)-7-(6-malonyl-beta-D-glucopyranosyloxy)-4H-1-benzopyran-4-one Natural products OC1C(O)C(O)C(COC(=O)CC(O)=O)OC1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 FRAUJUKWSKMNJY-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 240000008669 Hedera helix Species 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 241000605385 Ruscus Species 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- UCTLHLZWKJIXJI-LXIBVNSESA-N [(3s,8r,9s,10r,13s,14s)-17-chloro-16-formyl-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]12)C[C@]3(C)C(Cl)=C(C=O)C[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 UCTLHLZWKJIXJI-LXIBVNSESA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 229920000800 acrylic rubber Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 1
- 229940011658 asiatic acid Drugs 0.000 description 1
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 1
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 1
- 229940022757 asiaticoside Drugs 0.000 description 1
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229940085262 cetyl dimethicone Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000004387 flavanoid group Chemical group 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- SLRCCWJSBJZJBV-BYNSBNAKSA-N genisteine Chemical compound C1N2CCCC[C@@H]2[C@@H]2CN3CCCC[C@@H]3[C@H]1C2 SLRCCWJSBJZJBV-BYNSBNAKSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 235000019866 hydrogenated palm kernel oil Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000000940 lipogenetic effect Effects 0.000 description 1
- 239000008308 lipophilic cream Substances 0.000 description 1
- 230000003212 lipotrophic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- PRAUVHZJPXOEIF-AOLYGAPISA-N madecassic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2[C@H](O)C[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C PRAUVHZJPXOEIF-AOLYGAPISA-N 0.000 description 1
- 229940011656 madecassic acid Drugs 0.000 description 1
- BUWCHLVSSFQLPN-UHFFFAOYSA-N madecassic acid Natural products CC1CCC2(CCC3(C)C(=CCC4C5(C)CC(O)C(O)C(C)(C5CCC34C)C(=O)O)C2C1C)C(=O)OC6OC(COC7OC(CO)C(OC8OC(C)C(O)C(O)C8O)C(O)C7O)C(O)C(O)C6O BUWCHLVSSFQLPN-UHFFFAOYSA-N 0.000 description 1
- MTXMHWSVSZKYBT-UHFFFAOYSA-N malonyl daidzin Natural products OC1C(O)C(O)C(COC(=O)CC(O)=O)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 MTXMHWSVSZKYBT-UHFFFAOYSA-N 0.000 description 1
- MTXMHWSVSZKYBT-ASDZUOGYSA-N malonyldaidzin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CC(O)=O)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 MTXMHWSVSZKYBT-ASDZUOGYSA-N 0.000 description 1
- FRAUJUKWSKMNJY-RSEYPYQYSA-N malonylgenistin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CC(O)=O)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 FRAUJUKWSKMNJY-RSEYPYQYSA-N 0.000 description 1
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-M nonanoate Chemical compound CCCCCCCCC([O-])=O FBUKVWPVBMHYJY-UHFFFAOYSA-M 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940100518 polyglyceryl-4 isostearate Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 229940032044 quaternium-18 Drugs 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000027272 reproductive process Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及异黄酮在制备促进减肥的局部用组合物中的应用,特别是用于对抗局部超重;有关的美容方法以及一种除了异黄酮外还包含槐花提取物的组合物。
Description
本发明涉及异黄酮在制备促进减肥的局部用组合物中的应用,以及有关的美容方法。
在本发明的文本中,减肥优选为对抗局部超重的情况。
这种局部超出的重量以脂肪的形式出现,脂肪的数量和分布因性别不同而不同。因此,脂肪组织占女性体重的20-30%,占男性的10-15%。女性的皮下脂肪是男性的两倍厚。对男性来讲,脂肪堆积在腰部周围和以上部位(雄性分布,新陈代谢危险因素),而对女性来讲,脂肪集中在腰部以下,在臀部-大腿部分(雌性分布,与血管危险性没有关系)。这种堆积的较低位置的体脂的一个特征是其很难被动用。这种脂肪倾向于确保生殖过程中的能量需求(怀孕、更重要的是母乳喂养),因此组成了人体内最大的能量储存库。
在细胞水平上,脂肪细胞是球形细胞,其细胞内部的空间被充满甘油三酸酯的大液泡占据。该脂肪细胞的体积能快速变化。具体说来,取决于周围环境,这种细胞的直径可以达到40-120μm,这相当于体积增大27倍。在某些极端情况下,体积能增大到40倍。因此,由于脂肪细胞能快速储存(摄取或生成脂肪)或相反地,调动(脂肪分解)作为身体的主要能量来源的甘油三酸酯,脂肪细胞是人体的主要能量因素。
脂肪生成通过合成三酰基甘油来进行,三酰基甘油由3-磷酸甘油酯与活性脂肪酸的酯化作用生成;相反地,脂肪分解相当于储存的三酰基甘油水解成甘油和脂肪酸。已经发现了控制脂肪分解和脂肪生成的各种不同机理,所述机理涉及受体,例如α-2和/或β-1和β-2受体、A1类型腺苷受体、YY类型的前列腺素E2、Y2和神经肽NPY受体,还涉及到性激素。
因此,关于控制脂肪细胞分解和生成的机理知识已得到了显著的提高。然而,由于已知的减肥活性剂整体上不能令人满意,减肥活性剂仍在探索之中。因此目前存在着开发能有效地促进减肥的局部用组合物的真实需求。
两种主要类型的减肥活性剂是已知的有:脂肪分解剂(作用于清除多余的脂类)和脂肪还原剂(对抗脂肪的形成)。
a)脂肪分解剂
七叶树皂角素和白果:α2阻滞剂;
鞘氨醇:限制葡萄糖的穿透
b)脂肪还原剂
芸香苷(从芸香属之一种中提取):隔离葡萄糖,防止其与游离的脂肪酸结合。
可以在这些特定的活性剂中加入经常与减肥活性剂结合使用的抗浸润活性剂和静脉用试剂(venotomic agent)。
抗浸润活性剂:
山金车酊(抗水肿、镇静)
野生三色堇(在水分平衡中起重要作用)
墨角藻(fucus vesiculosus)(抗水肿、镇静)
静脉用试剂:
白果(对抗血管和毛细管的阻塞)
最后,含有这些已知减肥活性剂的配方物还可以包含用来对抗皮肤松弛的重构和光滑活性剂。
目前已发现含有一种或多种异黄酮的局部用组合物有减肥的作用,使其可能用于专门对抗局部超重。
专利申请文本WO 01/64177(Henkel KGAA)公开了含有黄酮、异黄酮、糖基和可选地一种刺激和/或去极化神经纤维的组合物在蜂窝状脂肪团的美容或使皮肤柔韧中的应用。
在文章Cosmetics,D.Schmid等,SOFW-Journal,127,Jahrgang10-200,“Genisteine,a new cosmetic ingredient derived from soy”中描述了某些异黄酮的抗蜂窝状脂肪团作用。然而,蜂窝状脂肪团的情况完全不同于局部超重。
因此,将蜂窝状脂肪团定义为皮下组织的局部代谢紊乱,该紊乱对体形造成损害。相反地,超重是由脂肪细胞的肥大或增生(提高了脂肪生成),或脂肪水解的减少造成的。由于蜂窝状脂肪团只影响女性的真皮(皮下组织),而超重(脂肪细胞)对两性的都有影响,这也是蜂窝状脂肪团-减肥的区别。而且,女性即使不超重也会有蜂窝状脂肪团;这是真皮/皮下构造的问题。
专利申请EP 829 621涉及含有异黄酮的组合物,该异黄酮通过降解堆积在脂肪细胞中的脂肪来实现减轻的效果。然而,在所述专利申请中没有提及局部给药的方式。
因此本发明的一个主题是异黄酮在制备促进减肥的局部用组合物中的应用,以及有关的美容方法。
按照本发明,所使用的“异黄酮”可以是从天然产品中提取的天然物质,特别是从例如大豆、三叶草、羽扁豆、苹果种的植物中提取。按照本发明的局部用组合物通常含有不同异黄酮的混合物,但在本发明文本中,异黄酮也可以以纯净的形式存在。而且,区分了异黄酮的糖苷配基形式和糖基化形式。这些不同的形式通常发现为混合物。用下列结构式来说明这些不同的形式。
具有如下结构式的糖苷配基形式
其中,R′1为氢原子或羟基,R′2为氢原子或甲氧基,以及R′3为羟基。
有利地是,按照本发明,R′1、R′2和R′3为:
R′1 R′2 R′3 化合物名称
H H OH 黄豆苷原
OH H OH 染料木黄酮
H OCH3 OH 黄豆黄素
具有如下结构式的糖基化形式:
其中,R′4为氢原子或羟基,R′5为氢原子或甲氧基,R′6为氢原子。
有利地是,按照本发明,R′4、R′5和 R′6为:
R′4 R′5 R′6 化合物名称
H H H 黄豆苷
OH H H 染料木苷
H OCH3 H Glycitine
异黄酮的糖基化形式是在自然界中最丰富的形式。
优选的异黄酮是天然异黄酮,例如染料木黄酮(1)、黄豆苷原或黄豆黄素。
特别地,可以用于本发明的染料木黄酮或4,5,7-三羟基-异黄酮可以是植物来源的产品,特别是大豆的产品,其染料木黄酮的滴定量为85重量%-90重量%,特别是Buckton Scott公司出售的名称为“85%-滴定量的染料木黄酮”的产品。
在本发明中,可以单独或以混合物的形式使用异黄酮。
可以证明局部应用一种或多种异黄酮的组合物对怀孕妇女或已在6个月内生产的妇女特别有利。因此本发明的一个主题也是一种促进减肥的美容方法,特别是用于对怀孕妇女或已在6个月内生产的妇女的抗局部超重。具体说来,本发明的组合物的一个优点是无需存在由于其毒性而对于怀孕或母乳喂养的妇女是禁忌的酒精。例如,咖啡因是一种非常常用的减肥试剂,需要溶解在酒精中,这在本发明中就可以避免了。
按照本发明,术语“减肥”和“对抗局部超重”是指一种可以避免或至少能减少如前所述的皮下脂肪的形成的行为。该行为特别是反映为减少难看的多余的脂肪或储藏的脂肪、使侧影优雅、促进多余脂肪的清除、更好地勾画体形或重塑侧影。
按照本发明,“对抗局部超重的美容方法”的表达指的是使用美容,使其能明显的估量上述行为。
因此,按照本发明的一种或多种异黄酮的局部用组合物可以用于易于形成局部超重的皮肤区域,即已形成或正在形成多余脂肪的区域。
例如,可用于本发明的含有染料木黄酮的组合物可含有基于组合物总重量的0.0085重量%-8.5重量%的染料木黄酮,即,对于染料木黄酮的重量滴定量为85%-90%的溶液,该溶液相对于组合物的总重量的重量百分比为0.01%-10%。
通常,可用于本发明的含有一种或多种异黄酮的组合物可含有基于组合物总重量的0.01%-10重量%、优选0.1%-3重量%的异黄酮。
使本发明能够实行的组合物含有美容业可以接受的载体,即能与皮肤兼容、通常用于局部的任何草药形式的载体,特别是以水溶液、水-醇溶液或油溶液、水包油或油包水或复合乳液、水或油凝胶、液体、面糊状或固体的无水产品、油在小球体的帮助下在水相中的分散相的形式,其中所述小球体可以是聚合物纳米颗粒,例如纳米小球和纳米胶囊或更好地是静止的离子或非离子型的脂囊泡。
该组合物可以或多或少具有流动性,其外观可以是白色或彩色霜、药膏、乳状液、乳液、浆液、面糊、摩丝或凝胶。
可选地,该组合物可以以气溶胶的形式用于皮肤。其还可以是固体形式,例如棒状。
本发明的组合物还可以含有化妆品中常见的助剂,例如亲水性或亲脂性胶凝剂、亲水性或亲脂性活性剂、防腐剂、抗氧化剂、溶剂、香料、螯合剂、去味剂和染料。这些不同的助剂的用量为本领域中常规用量,例如占组合物总重量的0.01%-20%。根据其性质,可以将这些助剂引入脂肪相、水相、脂囊泡或纳米颗粒中。
当本发明的组合物是乳液时,脂肪相的比例以组合物总重量计可为5%-80%,优选5%-50%。用于乳液状的组合物的油、乳化剂和助乳化剂为本领域中常用的产品。乳化剂和助乳化剂在本发明中的比例以组合物的总重量计为0.3%-20%,优选0.5%-20%。
可以用于本发明的组合物的油可以由矿物油、植物油(杏仁油、向日葵油、李子油)、动物油、合成油、硅油和氟油(全氟化聚醚)制成。脂肪醇(十六烷醇)、脂肪酸和蜡(蜂蜡)也可以用作脂肪物质。
可以用于本发明的乳化剂和助乳化剂的例子包括聚乙二醇的脂肪酸酯,例如PEG-40硬脂酸酯和PEG-60硬脂酸酯,以及多元醇的脂肪酸酯,例如甘油硬脂酸酯和山梨聚糖三硬脂酸酯。
特别可提及的亲水性胶凝剂包括羧基乙烯基聚合物(carbomer)、丙烯酸共聚物如丙烯酸酯/烷基丙烯酸酯共聚物、聚丙烯酰胺、多糖、天然树胶和粘土,提及的亲脂性胶凝剂包括例如膨润土的改性粘土、脂肪酸的金属盐、疏水性硅石和聚乙烯。
根据本发明使用的组合物可以含有其他具有减肥作用的活性剂,例如在介绍中所描述的脂肪分解剂和脂肪还原剂。
因此本发明涉及异黄酮在制备促进减肥、特别是对抗局部超重的局部用组合物中的应用,其特征在于同时、单独或按时间顺序次序使用一种或多种异黄酮、一种或两种脂肪分解型的减肥活性剂和/或一种或两种脂肪还原型的减肥活性剂。
脂肪分解型的减肥活性剂可以选自:咖啡因、rhodysterol、棕榈酰肉碱、α和β生物活性剂、七叶树皂角素、白果或鞘氨醇。脂肪还原型的减肥活性剂选自:安迪罗巴、藤黄果或芸香苷。
除了使用本发明的组合物,还可以同时、单独或按时间顺序次序使用一种或两种抗浸润活性剂或静脉用活性剂。浸润活性剂或静脉用活性剂可以选自:荚蒾、常春藤、山金车酊、Mouseear山柳菊、三色堇、墨角藻、假叶树、白果或七叶树皂角素。
本发明使用的组合物还可以含有其他活性剂,例如:
-槐花提取物:该提取物富含黄烷类(清除自由基)和芸香苷。该活性剂能促进毛细管循环,促进和激活组织的排泄和抗侵润;
-雷公根提取物:起源于东非和马达加斯加的雷公根提取物。该活性剂含有对组织有排泄、抗浸润和固化性质的萜烃(积雪草甙、亚细亚酸和羟基积雪草酸)。该提取物特别用于减肥产品,但也用于减除妊娠纹、抗皱和干燥用(siccatrizing)产品;因此减肥组合物中可以存在0-5%的雷公根提取物。
-“大豆蛋白质水解物”:大豆蛋白质是弹性调节剂。这些大豆缩氨酸可以是按照本领域的技术人员所公知的操作条件从大豆中提取的蛋白质的水解中获得的,即可以是任一种大豆蛋白质水解物。大豆缩氨酸,已在专利申请WO 00/19974中描述过,特别适用于本发明中的组合物。该活性剂能恢复细胞更新的机制、激活细胞外基质的结构组分的合成,具有修护、再生和固化的作用;在减肥组合物中可以含有0-5%的大豆蛋白质。
-抗皱活性剂,其可以由鳄梨呋喃、视黄醇及其衍生物、维生素C或大豆的未皂化物等制成。
特别优选分别提取的或作为混合物的两种活性异黄酮与槐花提取物的结合物,含有该结合物的组合物为本发明的一部分。该组合物可以含有0.01%-20%的槐花的提取物。
下列实施例用来说明本发明。
实施例1:修护凝胶
成分(INCI-EU) | %w/w |
水 | qsp |
PEG-6 | 3.6000 |
丁二醇 | 2.7000 |
糊精 | 1.8600 |
苯基三甲基硅油 | 1.2000 |
丙烯酸酯/C10-30烷基丙烯酸酯交联聚合体(crosspolymer) | 0.6000 |
防腐剂体系 | qsp |
二甲基硅油/苯基乙烯基二甲基硅油聚合体 | 0.3000 |
香料 | qs |
槐花提取物 | 0.01-20 |
黄原胶 | 0.1500 |
PPG 26-Buteth-26 | 0.1100 |
Genosten4000(1) | 1-10 |
大豆蛋白质水解物 | 0.1000 |
葡萄糖 | 0.0800 |
PEG 40加氢蓖麻油 | 0.0700 |
山梨醇 | 0.0400 |
雷公根提取物 | 0.01-5 |
柠檬酸 | 0.0200 |
扁浒苔提取物 | 0.01-5 |
着色剂 | qs |
氢氧化钠 | qsp pH=4.5-6.5 |
qs=足够量
qsp=为...的足够量
(1)由Nutrinov公司出售
通过物理提取法获得的富含异黄酮的大豆提取物:
4%异黄酮含有:
黄豆苷 0.28g
O.丙二酰黄豆苷 0.93g
染料木苷 0.28g
O.丙二酰染料木苷 2.50g
染料木黄酮 0.02g
大豆黄素 0g
实施例2:修护凝胶
成分(INCI-EU) | %w/w |
水 | qsp |
PEG-6 | 3.6000 |
丁二醇 | 2.7000 |
糊精 | 1.8600 |
苯基三甲基硅油 | 1.2000 |
丙烯酸酯/C10-30烷基丙烯酸酯交联聚合体 | 0.6000 |
防腐剂体系 | qsp |
二甲基硅油/苯基乙烯基二甲基硅油聚合体 | 0.3000 |
香料 | qs |
槐花提取物 | 0.01-20 |
黄原胶 | 0.1500 |
PPG 26-Buteth-26 | 0.1100 |
4,5,7-三羟基异黄酮 | 0.01-10 |
大豆蛋白质水解物 | 0.1000 |
葡萄糖 | 0.0800 |
PEG 40加氢蓖麻油 | 0.0700 |
山梨醇 | 0.0400 |
雷公根提取物 | 0.01-5 |
柠檬酸 | 0.0200 |
扁浒苔提取物 | 0.01-5 |
着色剂 | qs |
氢氧化钠 | qsp pH=4.5-6.5 |
qs=足够量
qsp=为...的足够量
实施例3:水包油乳霜
成分(INCI-EU) | %w/w |
水 | qsp |
饱和性角鲨烯 | 5.00 |
凡士林 | 5.00 |
甘油 | 5.00 |
异癸基新戊酸酯 | 5.00 |
季戊四醇四乙基己酸酯 | 5.00 |
环甲基硅油 | 4.00 |
十六-十八烷基醇(cetearyl alcohol) | 3.00 |
十四烷基十四烷酸酯 | 2.00 |
Laureth-23 | 2.00 |
硅石 | 2.00 |
十七碳二烯炔呋喃 | 0.1-10 |
蜂蜡 | 1.00 |
菌核胶 | 1.00 |
PEG-6 | 1.00 |
聚丙烯酰胺 | 0.80 |
甘油硬脂酸酯 | 0.70 |
聚二甲基硅氧烷醇 | 0.70 |
十六-十八烷基葡糖苷 | 0.60 |
C13-14异链烷烃 | 0.40 |
柠檬酸 | 0.14 |
Laureth-7 | 0.10 |
Quimdis混合物(2) | 0.01-10 |
咖啡因 | 0.1-10 |
扁浒苔提取物 | 0.01-5 |
藤黄果提取物 | 0.01-10 |
白果提取物 | 0.01-10 |
槐花提取物 | 0.01-20 |
大豆蛋白质水解物 | 0.01-10 |
防腐剂体系 | qs |
香料 | qs |
qs=足够量
qsp=为...的足够量
(2)由Quimdis公司出售
在7和17%之间的异黄酮混合物
4-8%大豆黄素葡糖苷
2-5%glycitine葡糖苷
1-4%染料木黄酮葡糖苷
实施例4:水包油乳霜
成分(INCI-EU) | %w/w |
水 | qsp |
饱和性角鲨烯 | 5.00 |
凡士林 | 5.00 |
甘油 | 5.00 |
异癸基新戊酸酯 | 5.00 |
季戊四醇四乙基己酸酯 | 5.00 |
环甲基硅油 | 4.00 |
十六-十八烷基醇 | 3.00 |
十四烷基十四烷酸酯 | 2.00 |
Laureth-23 | 2.00 |
硅石 | 2.00 |
十七碳二烯炔呋喃 | 0.1-10 |
蜂蜡 | 1.00 |
菌核胶 | 1.00 |
PEG-6 | 1.00 |
聚丙烯酰胺 | 0.80 |
甘油硬脂酸酯 | 0.70 |
聚二甲基硅氧烷醇 | 0.70 |
十六-十八烷基葡糖苷 | 0.60 |
C13-14异链烷烃 | 0.40 |
柠檬酸 | 0.14 |
Laureth-7 | 0.10 |
4,5,7-三羟基异黄酮 | 0.01-10 |
咖啡因 | 0.1-10 |
扁浒苔提取物 | 0.01-5 |
藤黄果提取物 | 0.01-10 |
白果提取物 | 0.01-10 |
槐花提取物 | 0.01-20 |
大豆蛋白质水解物 | 0.01-10 |
防腐剂体系 | qs |
香料 | qs |
qs=足够量
qsp=为...的足够量
实施例5:油包水乳霜
成分(INCI-EU) | %w/w |
水 | qsp |
氢化聚异丁烯 | 7.00 |
异十六烷基硬脂酸酯 | 7.00 |
环甲基硅油 | 4.80 |
甘油 | 4.00 |
矿物油 | 3.00 |
氧化锌 | 3.00 |
丁二醇 | 2.00 |
异壬基异壬酸酯 | 2.00 |
蜂蜡 | 2.00 |
十六烷基二甲基硅油共聚醇 | 1.70 |
聚甘油基-4异硬脂酸酯 | 1.65 |
月桂酸己酯 | 1.65 |
酒石酸钠 | 1.60 |
氯化钠 | 1.00 |
PEG-6 | 1.00 |
4,5,7-三羟基异黄酮 | 0.01-10 |
视黄基棕榈酸酯 | 0.01-10 |
扁浒苔提取物 | 0.01-5 |
槐花提取物 | 0.01-20 |
雷公根提取物 | 0.01-5 |
大豆蛋白质水解物 | 0.01-10 |
防腐剂体系 | qs |
香料 | qs |
qs=足够量
qsp=为...的足够量
实施例6:唇膏
成分(INCI-EU) | %w/w |
蓖麻油 | qsp |
油醇 | 20.00 |
氢化棕榈仁油 | 17.00 |
坎台里蜡 | 11.00 |
聚甘油基-3蜂蜡 | 10.00 |
矿物油 | 9.57 |
十七烷基二烯炔呋喃 | 0.1-1 |
4,5,7-三羟基异黄酮(夸特宁)quaternium-18锂蒙脱石 | 0.01-1.10 |
二氧化钛 | 1.00 |
生育胺基乙酸酯 | 0.50 |
碳酸丙二酯 | 0.33 |
香料 | qs |
视黄醇 | 0.01 |
扁浒苔提取物 | 0.01-5 |
槐花提取物 | 0.01-20 |
雷公根提取物 | 0.01-5 |
大豆蛋白质水解物 | 0.01-10 |
qs=足够量
qsp=为...的足够量
实施例7:霜凝胶
成分(INCI-EU) | %w/w |
水 | qsp |
环甲基硅油 | 5.40 |
辛基棕榈酸酯 | 5.00 |
氢化可可甘油酯(cocoglycerides) | 3.00 |
二十烷基二十二醇 | 2.55 |
丙二醇 | 2.50 |
异癸基新戊酸酯 | 2.00 |
甘油硬脂酸酯 | 1.70 |
十六烷醇 | 1.30 |
硬脂酸 | 1.00 |
PEG-6 | 1.00 |
蜂蜡 | 0.40 |
C13-14异链烷烃 | 0.40 |
丁二醇 | 0.16 |
甘油 | 0.16 |
十六-十八烷基醇 | 0.10 |
十六烷基棕榈酸酯 | 0.10 |
可可甘油酯 | 0.10 |
Laureth-7 | 0.10 |
Novasoy混合物(3) | 0.01-10 |
扁浒苔提取物 | 0.01-5 |
槐花提取物 | 0.01-20 |
雷公根提取物 | 0.01-5 |
大豆蛋白质水解物 | 0.01-10 |
防腐剂体系 | qs |
香料 | qs |
qs=足够量
qsp=为...的足够量
(3)由ADM公司出售
异黄酮混合物最小为30%
染料木黄酮/黄豆苷/glycitine比:1.3/1.0/0.3
剂量例子:染料木黄酮:20.80%
glycitine:3.80%
黄豆苷: 12.00%。
实施例8:霜凝胶
成分(INCI-EU) | %w/w |
水 | qsp |
环甲基硅油 | 5.40 |
辛基棕榈酸酯 | 5.00 |
氢化可可甘油酯 | 3.00 |
二十烷基二十二醇 | 2.55 |
丙二醇 | 2.50 |
异癸基新戊酸酯 | 2.00 |
甘油硬脂酸酯 | 1.70 |
十六烷醇 | 1.30 |
硬脂酸 | 1.00 |
PEG-6 | 1.00 |
蜂蜡 | 0.40 |
C13-14异链烷烃 | 0.40 |
丁二醇 | 0.16 |
甘油 | 0.16 |
十六-十八烷基醇 | 0.10 |
十六烷基棕榈酸酯 | 0.10 |
可可甘油酯 | 0.10 |
Laureth-7 | 0.10 |
4,5,7-三羟基异黄酮 | 0.01-10 |
扁浒苔提取物 | 0.01-5 |
槐花提取物 | 0.01-20 |
雷公根提取物 | 0.01-5 |
大豆蛋白质水解物 | 0.01-10 |
防腐剂体系 | qs |
香料 | qs |
qs=足够量
qsp=为...的足够量
实施例9:喷雾
成分(INCI-EU) | %w/w |
水 | qsp |
甘油 | 4.00 |
蒙脱石 | 3.00 |
PEG | 3.00 |
甘氨酸 | 0.30 |
柠檬酸 | 0.09 |
4,5,7-三羟基异黄酮 | 0.01-10 |
扁浒苔提取物 | 0.01-5 |
槐花提取物 | 0.01-20 |
雷公根提取物 | 0.01-5 |
大豆蛋白质水解物 | 0.01-10 |
防腐剂体系 | qs |
香料 | qs |
qs=足够量
qsp=为...的足够量
实施例10:使用按照实施例1的修护凝胶的试验总结
本试验用来评价按照实施例1的修护凝胶的效力和可接受性,由92-100名已在3个月内生产和/或其身体皮肤(下腹部和大腿)有过量脂肪的使用者在正常使用条件下在8周的时间里,每天2次重复使用。
调查对象
对92(时间为2个月)-100(时间为1个月)名的调查对象的相关结果分析,及其物理特征如下所示:
时间为1个月的调查对象(100名使用者)
年龄 | 身体皮肤的性质 | “过敏性”皮肤 |
19-49岁(平均:30岁) | -干性:44%-中性:36%-干性—中性混合:20% | 35% |
应注意到,48名调查对象刚刚经历过她们的首次怀孕,44名已经分别怀孕过2次(23)、3次(20)或4次(1)。
时间为2个月的调查对象(92名使用者)
年龄 | 身体皮肤的性质 | “过敏性”皮肤 |
19-49岁(平均:30岁) | -干性:45%-中性:33.7%-干性—中性混合:20% | 37% |
应注意到,48名调查对象刚刚经历过她们的首次怀孕,40名已经分别怀孕过2次(21)或3次(19)。
试验方案
所研究的修护凝胶由使用者在家中正常的使用条件下平均每天2次(早晨和晚上)在身体(特别是大腿、髋部、下腹部和臀部)上使用1-2个月,而不是使用她们平常所使用的产品。
在试验结束时(时间为1和2个月)填写与产品的性质相适应的调查表并邮递回,该调查表特别包括下列与对抗超重的行为有关的问题。
已经发现由上述的92-100名女性使用了2个月的按照实施例1的修护凝胶特别有效,87%的调查对象判断其为“令人愉快”和“非常令人愉快”,67%判断其为“好”和“很好”。如下为其性能特点。
表现 | 时间为1个月的效果(100名使用者) | 时间为2个月的效果(92名使用者) |
表示为调查对象的百分比% | ||
减少的难看的多余部分 | 76 | 86 |
减少的难看的储备脂肪 | 70 | 80 |
优雅的侧影 | 75 | 87 |
“促进”多余部分的清除 | 74 | 86 |
塑造体形 | 70 | 90 |
更好的塑造体形 | 77 | 68 |
重塑侧影 | 60 |
Claims (19)
1.糖苷配基或糖基化形式的异黄酮在制备促进减肥的局部用组合物中的应用。
2.根据权利要求1所述的应用,其特征在于该局部用组合物用于对抗局部超重。
3.根据权利要求1所述的应用,其特征在于该局部用组合物用于使侧影优雅、促进多余脂肪的清除、更好地勾画体形和/或重塑侧影。
4.根据权利要求1-3任一所述的应用,其特征在于同时、单独或按时间顺序次序使用一种或多种异黄酮、一种或两种脂肪分解型的减肥活性剂和/或一种或两种脂肪还原型的减肥活性剂。
5.根据权利要求4所述的应用,其特征在于脂肪分解型的减肥活性剂选自:咖啡因、rhodysterol、棕榈酰肉碱、α和β生物活性剂、七叶树皂角素、白果或鞘氨醇。
6.根据权利要求4或5所述的应用,其特征在于脂肪还原型的减肥活性剂选自:安迪罗巴、藤黄果或芸香苷。
7.根据权利要求1-6任一所述的应用,其特征在于一种或两种抗浸润活性剂或静脉用活性剂选自:荚蒾、山金车酊、Mouseear山柳菊、三色堇、墨角藻、假叶树、白果或七叶树皂角素,同时、单独或按时间顺序次序使用所述活性剂。
8.根据权利要求1-7任一所述的应用,其特征在于还同时、单独或按时间顺序次序使用槐花、雷公根和/或大豆蛋白质的提取物。
9.根据权利要求1-8任一所述的应用,其特征在于异黄酮选自:染料木苷、黄豆苷原、黄豆黄素或其混合物;所述异黄酮为糖苷配基或糖基化形式。
10.根据权利要求8所述的应用,其特征在于染料木苷是大豆植物来源的。
11.一种促进减肥的美容方法,其特征在于局部应用含有一种或多种糖苷配基或糖基化形式的异黄酮的美容组合物。
12.一种对抗局部超重的美容方法,其特征在于局部应用含有一种或多种糖苷配基或糖基化形式的异黄酮的组合物。
13.一种用于使侧影优雅、促进多余脂肪的清除、更好地勾画体形和/或重塑侧影的美容方法,其特征在于局部应用含有一种或多种糖苷配基或糖基化形式的异黄酮的组合物。
14.根据权利要求11-13任一所述的美容方法,其特征在于将权利要求4-8任一所述的一种或多种异黄酮和活性剂同时、单独或按时间顺序次序局部应用于倾向于形成局部超重的皮肤处。
15.根据权利要求11-14任一所述的美容方法,其特征在于异黄酮选自:染料木苷、黄豆苷原、黄豆黄素或其混合物;所述异黄酮为糖苷配基或糖基化形式。
16.根据权利要求15所述的美容方法,其特征在于染料木苷是大豆植物来源的。
17.根据权利要求11-16任一所述的美容方法,其特征在于对怀孕妇女或已在6个月内生产的妇女进行调理。
18.一种美容用组合物,其特征在于其含有一种或多种糖苷配基或糖基化形式的异黄酮和槐花提取物。
19.根据权利要求18所述的美容用组合物,其特征在于异黄酮选自:染料木苷、黄豆苷原、黄豆黄素或其混合物;所述异黄酮为糖苷配基或糖基化形式。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR02/07995 | 2002-06-27 | ||
FR0207995A FR2841470B1 (fr) | 2002-06-27 | 2002-06-27 | Utilisation d'isoflavones pour la preparation de compositions topiques utiles pour favoriser l'amincissement et methode de traitement cosmetique associee |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1671354A true CN1671354A (zh) | 2005-09-21 |
Family
ID=29724931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA038180170A Pending CN1671354A (zh) | 2002-06-27 | 2003-06-25 | 异黄酮在促进减肥中的应用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20050256061A1 (zh) |
EP (1) | EP1515696B1 (zh) |
CN (1) | CN1671354A (zh) |
AU (1) | AU2003264673A1 (zh) |
CA (1) | CA2491150A1 (zh) |
DE (1) | DE60322898D1 (zh) |
ES (1) | ES2311730T3 (zh) |
FR (1) | FR2841470B1 (zh) |
HK (1) | HK1074404A1 (zh) |
MX (1) | MXPA05000073A (zh) |
WO (1) | WO2004002435A2 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102488210A (zh) * | 2011-12-27 | 2012-06-13 | 西南大学 | 染料木素水凝胶的复合物及其制备方法 |
CN103379910A (zh) * | 2010-12-22 | 2013-10-30 | 法国科延公司 | 白花菜地上部分提取物及包含其的化妆品、皮肤病学或药物组合物 |
CN105520880A (zh) * | 2016-01-20 | 2016-04-27 | 广州丹奇日用化工厂有限公司 | 瘦身化妆品组合物 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2856294B1 (fr) | 2003-06-18 | 2005-08-05 | Expanscience Lab | Utilisation cosmetique d'une composition comprenant au moins une oxazoline, a titre de principe actif, comme amincissant et/ou pour prevenir et/ou traiter la cellulite |
FR2870743B1 (fr) * | 2005-03-21 | 2012-03-09 | Expanscience Lab | Utilisation d'alkyle furannes pour la preparation d'un medicament destine au traitement de l'obesite et pour le traitement cosmetique de la surcharge ponderale |
ATE506051T1 (de) | 2004-05-28 | 2011-05-15 | Expanscience Lab | Verwendung von furanalkylen zur kosmetischen behandlung von zellulitis |
ATE462431T1 (de) * | 2004-05-28 | 2010-04-15 | Expanscience Lab | Verwendung von furanalkylen zur herstellung eines arzneimittels für die behandlung von adipositas sowie kosmetische behandlung von übergewicht |
FR2870742B1 (fr) * | 2004-05-28 | 2008-03-14 | Expanscience Laboratoires Sa | Utilisation d'alkyle furannes pour la preparation d'un medicament destine au traitement du diabete, de l'obesite et pour le traitement cosmetique de la cellulite et de la surcharge ponderale |
FR2870740B1 (fr) * | 2005-03-21 | 2008-06-13 | Expanscience Sa Lab | Utilisation d'alkyle furannes pour le traitement cosmetique de la cellulite |
CN1960698A (zh) * | 2004-05-31 | 2007-05-09 | 昭和电工株式会社 | 含肉碱衍生物的局部减肥制剂和化妆品 |
US20060153926A1 (en) * | 2005-01-10 | 2006-07-13 | Bascom Charles C | Compositions, products and methods for controlling weight in a mammal |
DE102005021805B3 (de) | 2005-05-04 | 2006-10-05 | Lancaster Group Gmbh | Kosmetisches Verfahren zur Körpermodellierung mit Sonnenschutz und Modellierungs-Set |
DE102005032237A1 (de) * | 2005-07-07 | 2007-01-11 | Beiersdorf Ag | Emulgatorkombination für Kosmetika |
US20110274715A1 (en) * | 2008-05-22 | 2011-11-10 | Melissa France | Methods and compositions for cooling the human body |
KR101358718B1 (ko) * | 2011-06-10 | 2014-02-10 | 연세대학교 산학협력단 | 피마자 추출물 및 괴화 추출물을 유효성분으로 포함하며, 셀룰라이트 개선 효과가 있는 화장료 조성물 |
CN115245470A (zh) * | 2021-04-27 | 2022-10-28 | 山东本真化妆品有限公司 | 水包油乳液及其在对抗婴儿湿疹中的用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2829387B2 (ja) * | 1996-09-13 | 1998-11-25 | 農林水産省四国農業試験場長 | 脂肪細胞における脂肪分解促進用組成物 |
BR9908870A (pt) * | 1998-03-16 | 2000-11-21 | Procter & Gamble | Processos para regularizarem a aparência da pele |
DE10009423A1 (de) * | 2000-02-28 | 2001-09-06 | Henkel Kgaa | Kosmetische und pharmazeutische Zubereitungen |
DE10009424A1 (de) * | 2000-02-28 | 2001-09-06 | Henkel Kgaa | Verwendung von Flavonen oder Isoflavonen zur Cellulite-Behandlung |
AU2001253070A1 (en) * | 2000-03-31 | 2001-10-15 | Jonathan Ingram | Isoflavones for treatment of obesity |
EP1234572B1 (de) * | 2001-02-26 | 2013-10-30 | Mibelle AG Cosmetics | Isoflavon-Aglykone enhaltende Hautbehandlungsmittel |
FR2822068B1 (fr) * | 2001-03-15 | 2004-12-17 | Pharmascience Lab | Composition topique comprenant une association de lipides furanniques d'avocat et d'isoflavones |
WO2002087700A1 (en) * | 2001-04-26 | 2002-11-07 | The Procter & Gamble Company | Method, kit and device for the treatment of cosmetic skin conditions |
ITMI20011182A1 (it) * | 2001-06-05 | 2002-12-05 | Indena Spa | Composizioni farmaceutiche e/o cosmetiche per il trattamento di adiposita' localizzate e della cellulite |
-
2002
- 2002-06-27 FR FR0207995A patent/FR2841470B1/fr not_active Expired - Fee Related
-
2003
- 2003-06-25 CN CNA038180170A patent/CN1671354A/zh active Pending
- 2003-06-25 DE DE60322898T patent/DE60322898D1/de not_active Expired - Lifetime
- 2003-06-25 EP EP03761638A patent/EP1515696B1/fr not_active Expired - Lifetime
- 2003-06-25 MX MXPA05000073A patent/MXPA05000073A/es active IP Right Grant
- 2003-06-25 ES ES03761638T patent/ES2311730T3/es not_active Expired - Lifetime
- 2003-06-25 AU AU2003264673A patent/AU2003264673A1/en not_active Abandoned
- 2003-06-25 CA CA002491150A patent/CA2491150A1/fr not_active Abandoned
- 2003-06-25 WO PCT/FR2003/001956 patent/WO2004002435A2/fr active IP Right Grant
- 2003-06-25 US US10/519,096 patent/US20050256061A1/en not_active Abandoned
-
2005
- 2005-09-23 HK HK05108441A patent/HK1074404A1/xx not_active IP Right Cessation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103379910A (zh) * | 2010-12-22 | 2013-10-30 | 法国科延公司 | 白花菜地上部分提取物及包含其的化妆品、皮肤病学或药物组合物 |
CN103379910B (zh) * | 2010-12-22 | 2018-10-02 | 法国科延公司 | 白花菜地上部分提取物及包含其的化妆品、皮肤病学或药物组合物 |
CN102488210A (zh) * | 2011-12-27 | 2012-06-13 | 西南大学 | 染料木素水凝胶的复合物及其制备方法 |
CN105520880A (zh) * | 2016-01-20 | 2016-04-27 | 广州丹奇日用化工厂有限公司 | 瘦身化妆品组合物 |
Also Published As
Publication number | Publication date |
---|---|
CA2491150A1 (fr) | 2004-01-08 |
FR2841470B1 (fr) | 2006-01-13 |
US20050256061A1 (en) | 2005-11-17 |
HK1074404A1 (en) | 2005-11-11 |
DE60322898D1 (de) | 2008-09-25 |
AU2003264673A8 (en) | 2004-01-19 |
WO2004002435A2 (fr) | 2004-01-08 |
EP1515696B1 (fr) | 2008-08-13 |
EP1515696A2 (fr) | 2005-03-23 |
AU2003264673A1 (en) | 2004-01-19 |
WO2004002435A3 (fr) | 2004-05-13 |
FR2841470A1 (fr) | 2004-01-02 |
ES2311730T3 (es) | 2009-02-16 |
MXPA05000073A (es) | 2005-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1671354A (zh) | 异黄酮在促进减肥中的应用 | |
CN103585097B (zh) | 一种白及多糖载表皮生长因子复合物及其制备方法和应用 | |
KR101550179B1 (ko) | 탈모방지 및 모발성장 조성물 | |
KR20130137634A (ko) | 콜라겐 생산 촉진제, 히알루론산 생산 촉진제, 섬유아세포 증식 촉진제 및 항주름제 | |
CN106883959A (zh) | 一种香榧精油皂 | |
CN106110308A (zh) | 一种能让乳房丰满紧致和预防乳腺疾病的精华液 | |
KR20210017590A (ko) | 발효 식물성 오일 및 발효 식물성 추출물을 포함하는 화장료 조성물 | |
CN1173693C (zh) | 含氨基酚衍生物的化妆品组合物 | |
KR100984010B1 (ko) | 탈모 방지 및 발모 촉진용 조성물 | |
KR20190001166A (ko) | 미선나무 추출물을 활용한 피부 재생용 화장료 조성물 | |
JP2006137690A (ja) | 皮膚外用剤およびヒアルロン酸産生促進剤 | |
JP3991164B2 (ja) | ナツメ抽出物および胡桃抽出物を含む化粧料組成物 | |
CN109330927A (zh) | 一种滋润修复素颜霜及其制备方法 | |
CN1870971A (zh) | 用于改善皮肤皱纹的包含野桐提取物的化妆品组合物 | |
WO2006090940A1 (en) | Composγπon for prevention and treatment of stretch mark comprising citric acid, zinc and arginine | |
KR101761005B1 (ko) | 법제 유황을 포함하는 피부보습, 항염 및 면역 증강용 화장료 조성물 및 그 제조방법 | |
JP2000016916A (ja) | 脂肪分解促進剤および痩身用皮膚化粧料 | |
CN110384636A (zh) | 一种含依兰精油的美胸紧实按摩膏及其制备方法 | |
JP3249707B2 (ja) | 脂肪分解促進剤 | |
KR101724529B1 (ko) | 홍해삼 추출물을 흑효모 균사체로 발효한 홍해삼 흑효모 발효액을 포함하는 화장료 조성물 | |
EP2046356B1 (fr) | Utilisation d'un extrait de gleditsia en cosmétique et en dermatologie | |
KR100807842B1 (ko) | 냄새 제거용 항균성 조성물 | |
CN107693411A (zh) | 一种具有抗炎功效的向日葵芽和鹰嘴豆籽提取物的组合物 | |
KR20090003828A (ko) | 탈모방지 및 발모 조성물을 함유하는 헤어토닉 | |
KR100983076B1 (ko) | 피부 크림 화장용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Open date: 20050921 |